NEW YORK CITY, NY — September 17, 2025 — Leads & Copy — Visionary Holdings Inc. (NASDAQ:GV) has partnered with Jiangsu Yike Regenerative Medicine to collaborate on research, development, and commercialization in cellular rejuvenation and aesthetic treatment. The partnership signifies GV’s entry into the Consumption Healthcare sector, focusing on the Medical Aesthetics industry and aesthetic treatment sub-segment, applying biotechnology developed by Yike to drive innovation and growth.
Yike will lead the project and fund R&D, securing related intellectual property. GV will then evaluate outcomes and may acquire or license rights through purchase or leasing agreements, with consideration in cash or GV shares.
GV and Yike will collaborate in cell activation and telomerase homeostasis, smart delivery and personalized solutions, and stem cell and immune cell applications. GV will work with Dr. Zhenyu Ju, Chief Scientist of Yike, an expert in aging and regenerative medicine.
In June 2025, GV established Visionary Health Technology Group Limited in Hong Kong as its Asia-Pacific headquarters to oversee this collaboration.
Dr. Zhenyu Ju, Chief Scientist of Yike.
Contact: IR@visionary.holdings
Source: Visionary Holdings Inc.
